Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis

Main Article Content

Francisco Kerdel
Christina Don
Renata Block
Caitlin Lewis
Rhonda Schreiber


psoriasis, calcipotriene


Abstract not available.


1. Gupta R, Debbaneh MG, Liao W, Genetic Epidemiology of Psoriasis. Curr Dermatol Rep. 2014 March; 3(1):61-78.

2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is
associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9.

3. Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012 Oct;9(10):1263-71.

4. Stein Gold LF. Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence. Semin Cutan Med Surg. 2016 Mar;35(2 Suppl 2):S36 44; quiz S45.

5. Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L. The Clinical
Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes. J Drugs Dermatol. 2019 Feb 1;18(2s):s100-s107.

6. Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 July;94(1):46-53.

7. Feldman, SR, Mills, M, Brundage, T, & Eastman, WJ (2013, March). A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. JDD, 12(3), 300-306.

8. Data on File, Mayne Pharma, Inc.

Most read articles by the same author(s)

1 2 > >>